New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 15, 2014
13:15 EDTSNYSanofi announces results comparing Lantus to insulin detemir
Sanofi announced results from a real world outcome study of type 2 diabetes, T2D, patients that show switching from Lantus, insulin glargine rDNA origin injection, to insulin detemir demonstrated higher average blood sugar levels, A1C and lower A1C reduction over a span of 12 months compared to maintaining patients on Lantus. Alternatively, switching patients from insulin detemir to Lantus resulted in a significantly lower A1C compared to maintaining patients on insulin detemir. The study findings were presented at the 74th Scientific Sessions of the American Diabetes Association in San Francisco, Calif.
News For SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 9, 2014
11:19 EDTSNYSanofi reportedly ready to make acquisitions in animal medicine, Bloomberg says
Subscribe for More Information
December 4, 2014
11:12 EDTSNYSanofi diabetes sales head left company, Bloomberg says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use